Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

SeaStar Medical Holding Corp

NASDAQ: ICU · Industrial Applications and Services · 4 alerts · CIK 1831868

Share price
$0.8535Close, Nov 16
Market cap
$4.54M
Shares outstanding
5.32MLatest SEC cover page
Sector
Industrial Applications and Services
Industry
Surgical & Medical Instruments & ApparatusSIC 3841

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All SeaStar Medical Holding Corp filings on SEC EDGAR ↗

8:16 AM ET 10-Q
Financial Results

SeaStar Medical Holding Q3 2026 Results: Net Loss of $4.53M, Loss Widens

SeaStar Medical reported a net loss of $11.8 million for the nine months ended September 30, 2026, compared to $9.2 million in the prior year period, driven by increased research and development expenses. Total revenue grew to $1.7 million from $0.8 million year-over-year, while cash reserves decreased significantly to $4.0 million from $12.0 million at the start of the year.

Key figure
Net loss $4.53M
8:00 AM ET 8-K
Financial Results

SeaStar Medical Holding Financial Results

SeaStar Medical reported Q3 2026 financial results, highlighted by a 247% increase in net revenue to $635,000 driven by adoption of its QUELIMMUNE therapy. The company also announced that its NEUTRALIZE-AKI pivotal clinical trial for adult patients is nearly 75% enrolled and it has submitted the first module of its PMA application to the FDA.

Term
Q3 2026

“The strength of the QUELIMMUNE therapy adoption in this ultra-rare pediatric AKI market provides great promise for our pipeline indications. And we continue to build momentum in educating the critical care pediatric health care community.”

Eric Schlorff, CEO of SeaStar Medical

“The NEUTRALIZE-AKI pivotal clinical trial has enrolled nearly 75% of its intended 339 patients, and we have already submitted the first module of the premarket approval application to the FDA in hopes that our modular submission will speed this potential approval.”

Eric Schlorff, CEO of SeaStar Medical

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.